VRDN 21.06 (-0.57%)
US92790C1045BiotechnologyBiotechnology

Viridian Therapeutics (VRDN) Stock Highlights

21.06 | -0.57%
2024-09-19 02:59:11
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Statistics

Range Today
20.61 22.65
Volume Today 1.58M
Range 1 Year
10.93 24.18
Volume 1 Year 262.3M
Range 3 Year
9.47 39
Volume 3 Year 503.96M
Range 10 Year
4.665 1304.78
Volume 10 Year 580.2M

Highlights

Market Capitalization 1.41B (small)
Floating Shares 52.74M
Current Price 21.06
Price To Earnings -5.08
Price To Revenue 3.38K
Price To Book 4.28
Earnings Per Share -4.25
Payout Ratio 0%

Performance

Latest -0.57%
1 Month +35.96%
3 Months +73.91%
6 Months +24.25%
1 Year +20.69%
3 Years +86.37%
5 Years +49.2%
10 Years -98.14%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.